Delivery at 37 Weeks Minimizes Dichorionic Twin Mortality

Share this content:
Delivery at 37 Weeks Minimizes Dichorionic Twin Mortality
Delivery at 37 Weeks Minimizes Dichorionic Twin Mortality

THURSDAY, Sept. 8, 2016 (HealthDay News) -- Delivery for dichorionic pregnancy should occur at 37 weeks to reduce the risk of stillbirth and newborn death, according to research published online Sept. 6 in The BMJ.

Fiona Cheong-See, M.B.B.S., of the Queen Mary University of London, and colleagues reviewed 32 studies that were conducted over the past 10 years and included 35,171 twin pregnancies (29,685 dichorionic and 5,486 monochorionic). The team compared the risk of stillbirth to the risk of newborn death. Newborn death was defined as death up to 28 days after delivery.

In dichorionic pregnancies, the risk of stillbirth and newborn death was balanced until 37 weeks' gestation. However, if delivery was delayed until 38 weeks, the risk of stillbirth went up by 8.8 deaths per 1,000 births. In monochorionic pregnancies, the risk of stillbirth appeared to be higher than newborn death if a pregnancy went longer than 36 weeks. Rates of neonatal morbidity showed a consistent reduction with increasing gestational age.

The results suggest that delivery for dichorionic pregnancies should be considered at 37 weeks' gestation "to prevent the significant increase in stillbirths associated with expectant management compared with the risk of neonatal deaths associated with early delivery," the authors write. And, for monochorionic pregnancies, "there is no clear evidence to support routine delivery before 36 weeks' gestation."

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »